Innovative therapy of ovarian cancer based on overexpression of CD44 receptor
Barbara Bukowska, Agnieszka Marczak
DOI: 10.17772/gp/2428
·
Ginekol Pol 2015;86(5).
open access
Vol 86, No 5 (2015)
ARTICLES
Abstract
Ovarian carcinoma constitutes the main cause of cancer-related death among women. The curability rates remain
low despite rapid advances in medicine. Thus, the search for new and improved methods continues, with CD44-
targeting as one of them. CD44 is a cell-surface glycoprotein, which binds to its ligand – hyaluronic acid (HA) –
and regulates crucial processes such as cell differentiation, proliferation and migration. Overexpression of CD44,
observed in many ovarian cancer cells, is used in creating carriers for selective delivery of various drugs (paclitaxel,
doxorubicin, camptothecin or cisplatin) to cancer cells.
In this article, we summarized the current state of knowledge regarding CD44-targeting as a new and more efficient
way of ovarian cancer treatment, with high potential and promising therapeutic perspectives.
Abstract
Ovarian carcinoma constitutes the main cause of cancer-related death among women. The curability rates remain
low despite rapid advances in medicine. Thus, the search for new and improved methods continues, with CD44-
targeting as one of them. CD44 is a cell-surface glycoprotein, which binds to its ligand – hyaluronic acid (HA) –
and regulates crucial processes such as cell differentiation, proliferation and migration. Overexpression of CD44,
observed in many ovarian cancer cells, is used in creating carriers for selective delivery of various drugs (paclitaxel,
doxorubicin, camptothecin or cisplatin) to cancer cells.
In this article, we summarized the current state of knowledge regarding CD44-targeting as a new and more efficient
way of ovarian cancer treatment, with high potential and promising therapeutic perspectives.
Get Citation
Keywords
targeted therapy / ovarian cancer / CD44 /
About this articleTitle
Innovative therapy of ovarian cancer based on overexpression of CD44 receptor
Journal
Issue
Page views
738
Article views/downloads
845
DOI
10.17772/gp/2428
Bibliographic record
Ginekol Pol 2015;86(5).
Keywords
targeted therapy / ovarian cancer / CD44 /
Authors
Barbara Bukowska
Agnieszka Marczak
